
The Hyderabad-based pharmaceutical firm had on October 13 reapplied to the Drugs Controller General of India (DCGI) seeking permission to conduct combined phase 2 and 3 human clinical trials of the vaccine in the country.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3k6H3JY
via
IFTTT
0 comments:
Post a Comment